Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Recs

0
Player Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:35:17 PM : Outperform Start Price: $6.32 FOLD Score: -81.27

Biotech

Featured Broker Partners


Advertisement